A Case of Recurrent Ovarian Cancer and Therapy-Related Acute Myeloid Leukemia Treated with Azacitidine

• Published in: Case reports in oncology Vol. 14; no. 3; pp. 1847 - 1852
• Main Authors: Ando, Kenju, Shimomura, Akihiko, Nasu, Ryo, Nakanishi, Misao, Kawamura, Yukino, Hangaishi, Akira, Oishi, Hajime, Shimizu, Chikako
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 27.12.2021; Karger Publishers
• Subjects: Anemia; azacitidine; Bone marrow; Cancer therapies; carboplatin; Case Report; Case reports; Chemotherapy; Cytogenetics; Cytotoxicity; Gynecology; Leukemia; Medical prognosis; Myelodysplastic syndromes; Obstetrics; Ovarian cancer; paclitaxel; Patients; Radiation therapy; Stem cell transplantation; therapy-related acute myeloid leukemia; Thrombocytopenia; Tumors; Thrombocytopenia; Carboplatin; Therapy-related acute myeloid leukemia; Azacitidine; Paclitaxel; Ovarian cancer
• ISSN: 1662-6575; 1662-6575
• DOI: 10.1159/000521160

Abstract Therapy-related myelodysplastic syndrome (tMDS) and acute myeloid leukemia (tAML) are lethal complications of chemotherapy. The incidence rates are expected to increase owing to improvements of cancer treatment. Early diagnosis of tMDS/AML is crucial because AML progresses rapidly. Hematopoietic stem cell transplantation (HSCT) is the only current treatment to prolong survival; however, patients with tMDS/AML are more likely to be intolerable to HSCT if they have other active solid tumors. An effective treatment for patients with tMDS/AML who are not candidates for HSCT is not established. We present a case of tAML that developed during chemotherapy for treating active ovarian cancer. The patient presented with thrombocytopenia that was initially suggested to be chemotherapy-induced thrombocytopenia. The patient was not a candidate for HSCT because of active cancer. However, she was able to receive azacitidine because her ovarian cancer responded well to chemotherapy. Pancytopenia is a common symptom of both chemotherapy-induced bone marrow suppression and tMDS/AML; thus, it may be difficult to distinguish between them at the first presentation. Given the prediction that the tMDS/AML incidence will increase as the survival of cancer patients improves, oncologists should be aware of the risks of tMDS/AML in patients with a history of cytotoxic chemotherapy. Although the indications for intensive care of tAML for patients with active solid tumors are poor, some patients might be able to receive cytotoxic treatment for tAML if the active solid tumors remain stable. Further studies focused on tMDS/AML with active solid tumors are needed to develop an effective treatment.